1-(4-((6,7-Dimethoxyquinazolin-4-yl)oxy)naphthalen-1-yl)-3-(3-(trifluoromethyl)phenyl)urea

ID: ALA4077930

Chembl Id: CHEMBL4077930

PubChem CID: 137649571

Max Phase: Preclinical

Molecular Formula: C28H21F3N4O4

Molecular Weight: 534.49

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1cc2ncnc(Oc3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)c4ccccc34)c2cc1OC

Standard InChI:  InChI=1S/C28H21F3N4O4/c1-37-24-13-20-22(14-25(24)38-2)32-15-33-26(20)39-23-11-10-21(18-8-3-4-9-19(18)23)35-27(36)34-17-7-5-6-16(12-17)28(29,30)31/h3-15H,1-2H3,(H2,34,35,36)

Standard InChI Key:  CKEJPGSKHUMMNJ-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4077930

    ---

Associated Targets(Human)

MDA-MB-435 (38290 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HUVEC (11049 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A-431 (6446 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FGFR4 Tclin Fibroblast growth factor receptor 4 (3668 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 534.49Molecular Weight (Monoisotopic): 534.1515AlogP: 7.26#Rotatable Bonds: 6
Polar Surface Area: 94.60Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.32CX Basic pKa: 2.89CX LogP: 6.22CX LogD: 6.22
Aromatic Rings: 5Heavy Atoms: 39QED Weighted: 0.24Np Likeness Score: -1.34

References

1. Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y..  (2018)  Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.,  61  (1): [PMID:29189002] [10.1021/acs.jmedchem.7b01091]
2. Tan L, Zhang J, Wang Y, Wang X, Wang Y, Zhang Z, Shuai W, Wang G, Chen J, Wang C, Ouyang L, Li W..  (2022)  Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.,  65  (7.0): [PMID:35311289] [10.1021/acs.jmedchem.1c01714]
3. Liang Q, Wang J, Zhao L, Hou J, Hu Y, Shi J..  (2021)  Recent advances of dual FGFR inhibitors as a novel therapy for cancer.,  214  [PMID:33556787] [10.1016/j.ejmech.2021.113205]

Source